| Income Statement | 2024-12-31 | |||
|---|---|---|---|---|
| Total revenue | 191,589 | |||
| Cost of product revenue | 12,550 | |||
| Research and development | 200,518 | |||
| Selling, general and administrative | 256,652 | |||
| Total operating expenses | 469,720 | |||
| Loss from operations | -278,131 | |||
| Interest and other income, net | 26,000 | |||
| Total interest and other income | 26,000 | |||
| Equity method investment loss | -6,000 | |||
| Net loss | -258,131 | |||
| Basic eps | -3.48 | |||
| Diluted eps | -3.48 | |||
| Basic average shares | 74,132,811 | |||
| Diluted average shares | 74,132,811 | |||
SpringWorks Therapeutics, Inc. (SWTX)
SpringWorks Therapeutics, Inc. (SWTX)